Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer
Frank Weinberg, Shirish GadgeelDivision of Hematology and Oncology, Department of Medicine, University of Michigan, Ann Arbor, MI, USAAbstract: Until recently, the treatment of patients with advanced non-small-cell lung cancer (NSCLC) whose tumors did not have a targetable genetic alteration was cyt...
Guardado en:
Autores principales: | Weinberg F, Gadgeel S |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/449832ce898049848b3bf1a0e69f940c |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Neoadjuvant immunotherapy combined with chemotherapy for locally advanced squamous cell lung carcinoma: A case report and literature review
por: Zheng Yuan, et al.
Publicado: (2021) -
Phase II Study of Nivolumab Plus Ipilimumab with Platinum-Based Chemotherapy for Treatment-Naïve Advanced Non-Small Cell Lung Cancer with Untreated Brain Metastases: NIke Trial (LOGiK2004)
por: Tsuchiya-Kawano Y, et al.
Publicado: (2021) -
Correlation between MTHFR 677C > T polymorphism and response of pemetrexed-based chemotherapy in advanced NSCLC: A meta-analysis
por: Han Feng, et al.
Publicado: (2021) -
Comparative effectiveness and safety of nab-paclitaxel plus carboplatin vs gemcitabine plus carboplatin in first-line treatment of advanced squamous cell non-small cell lung cancer in a US community oncology setting
por: Mudad R, et al.
Publicado: (2017) -
Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs)
por: Giustini N, et al.
Publicado: (2021)